FIG. 6.

Confirmation of the presence of capsids at the TGN by disruption of the TGN with nocodazole. To disrupt the TGN, mock-treated (A and B) or HSV-1 K26GFP-infected (C and D) 143B cells were treated with 20 μM nocodazole for the last 2 h of the 20°C chase and labeled with TGN46 primary antibodies (in red). Comparison between untreated (A and C) and treated (B and D) cells demonstrated a clear disruption of the TGN when nocodazole was added. K26GFP capsids (in green) largely remained associated with the TGN46 marker, even when the TGN was disrupted by the drug.